Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Lupus ; 23(4): 436-42, 2014 Apr.
Article in English | MEDLINE | ID: mdl-24399814

ABSTRACT

INTRODUCTION: Renal involvement is the most common serious complication in patients with systemic lupus erythematosus (SLE). OBJECTIVE: The objective of this article is to investigate and determine the associated factors of disease damage among lupus nephritis (LN) patients. METHODS: Medical records of LN patients who attended regular follow-up for at least one year in the Nephrology/SLE Clinic, Universiti Kebangsaan Malaysia Medical Centre (UKMMC), were reviewed. Their Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index scores were noted. Univariate analysis and multivariable regression analysis were performed to determine the independent factors of disease damage in LN. RESULTS: A total of 150 patients were included and their follow-up duration ranged from one to 20 years. Sixty (40%) LN patients had disease damage (SDI ≥1). In the univariate analysis, it was associated with age, longer disease duration, antiphospholipid syndrome (APS), higher maximum daily oral prednisolone dose (mg/day), lower mean C3 and C4, higher chronicity index and global sclerosis on renal biopsies (p < 0.05). Patients who received early (≤3 months after the SLE diagnosis) hydroxychloroquine (HCQ), optimum HCQ dose at 6.5 mg/kg/day and achieved early complete remission (CR) were less likely to have disease damage (p < 0.05). After adjustment for age, gender, disease duration and severity, multivariable regression analysis revealed that a higher maximum daily dose of oral prednisolone was independently associated with disease damage while early HCQ and CR were associated with lower disease damage. CONCLUSION: Higher maximum daily prednisolone dose predicted disease damage whereas treatment with early HCQ and early CR had a protective role against disease damage.


Subject(s)
Antiphospholipid Syndrome/epidemiology , Hydroxychloroquine/therapeutic use , Lupus Nephritis/physiopathology , Prednisolone/therapeutic use , Adult , Dose-Response Relationship, Drug , Female , Follow-Up Studies , Humans , Hydroxychloroquine/administration & dosage , Lupus Nephritis/epidemiology , Malaysia/epidemiology , Male , Middle Aged , Multivariate Analysis , Prednisolone/administration & dosage , Regression Analysis , Remission Induction , Retrospective Studies , Risk Factors , Severity of Illness Index , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...